CY1111853T1 - Θεση δεσμευσης υψηλης συγγενειας στον hgfr και μεθοδοι ταυτοποιησης ανταγωνιστων αυτου - Google Patents

Θεση δεσμευσης υψηλης συγγενειας στον hgfr και μεθοδοι ταυτοποιησης ανταγωνιστων αυτου

Info

Publication number
CY1111853T1
CY1111853T1 CY20111100917T CY111100917T CY1111853T1 CY 1111853 T1 CY1111853 T1 CY 1111853T1 CY 20111100917 T CY20111100917 T CY 20111100917T CY 111100917 T CY111100917 T CY 111100917T CY 1111853 T1 CY1111853 T1 CY 1111853T1
Authority
CY
Cyprus
Prior art keywords
hgfr
competitors
affinity binding
binding position
identification methods
Prior art date
Application number
CY20111100917T
Other languages
English (en)
Inventor
Paolo Maria Comoglio
Paolo Carminati
Paolo Michieli
Cristina Basilico
Original Assignee
Metheresis Translational Research Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Research Sa filed Critical Metheresis Translational Research Sa
Publication of CY1111853T1 publication Critical patent/CY1111853T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/4753Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Χρήση πολυνουκλεοτιδίου κωδικεύοντος ή πολυπεπτιδίου περιλαμβάνοντος τουλάχιστον τις εξωκυτταρικές επικράτειες ΙΡΤ-3 και ΙΡΤ-4 του υποδοχέα αυξητικού παράγοντα ηπατοκυττάρων για την εξέταση διαλογής και/ή ανάπτυξη φαρμακολογικά δραστικών μέσων χρήσιμων στην αγωγή καρκίνου, κατά προτίμηση καρκίνου με απορύθμιση του υποδοχέα αυξητικού παράγοντα ηπατοκυττάρων.
CY20111100917T 2008-05-14 2011-09-22 Θεση δεσμευσης υψηλης συγγενειας στον hgfr και μεθοδοι ταυτοποιησης ανταγωνιστων αυτου CY1111853T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08103958 2008-05-14
EP09159644A EP2119448B1 (en) 2008-05-14 2009-05-07 High affinity binding site of HGFR and methods for identification of antagonists thereof

Publications (1)

Publication Number Publication Date
CY1111853T1 true CY1111853T1 (el) 2015-11-04

Family

ID=40984839

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100917T CY1111853T1 (el) 2008-05-14 2011-09-22 Θεση δεσμευσης υψηλης συγγενειας στον hgfr και μεθοδοι ταυτοποιησης ανταγωνιστων αυτου

Country Status (18)

Country Link
US (4) US8404453B2 (el)
EP (1) EP2119448B1 (el)
JP (1) JP5623027B2 (el)
KR (1) KR101509263B1 (el)
AT (1) ATE513556T1 (el)
BR (1) BRPI0901502A2 (el)
CA (1) CA2665958C (el)
CY (1) CY1111853T1 (el)
DK (1) DK2119448T3 (el)
EA (1) EA017863B1 (el)
ES (1) ES2368603T3 (el)
HR (1) HRP20110643T1 (el)
IL (1) IL198545A0 (el)
MX (1) MX2009005049A (el)
PL (1) PL2119448T3 (el)
PT (1) PT2119448E (el)
SG (1) SG157312A1 (el)
SI (1) SI2119448T1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2785741A1 (en) * 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
WO2016079194A1 (en) * 2014-11-20 2016-05-26 Stichting Katholieke Universiteit A novel auto-active and intracellular mutant of met
IL265645B2 (en) * 2016-09-29 2024-05-01 Mitsubishi Tanabe Pharma Corp Monoclonal CMET binding agents, their drug conjugates and uses thereof
CN113567685B (zh) * 2021-09-26 2022-05-17 瑞博奥(广州)生物科技股份有限公司 基于核酸适配体探针的hgfr识别方法及检测hgfr的试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2104914T3 (es) * 1991-05-10 1997-10-16 Pharmacia & Upjohn Spa Formas truncadas del factor de crecimiento de hepatocitos (hgf).
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
AU2760602A (en) 2001-03-23 2002-09-26 Agouron Pharmaceuticals, Inc. Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase, and materials and methods for identification of inhibitors thereof
AU2004298483A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
WO2005108424A1 (en) 2004-05-06 2005-11-17 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
WO2007013603A1 (ja) * 2005-07-28 2007-02-01 Anges Mg, Inc. リンパ管新生促進剤
US7758862B2 (en) 2005-09-30 2010-07-20 Compugen Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
KR101429297B1 (ko) * 2006-02-06 2014-08-12 메테레시스 트랜스레이셔날 리서치 에스.에이. 종양 치료를 위한 항-Met 단클론 항체, 이의 단편과벡터 및 상응하는 산물
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof

Also Published As

Publication number Publication date
US20120115219A1 (en) 2012-05-10
US9121854B2 (en) 2015-09-01
KR20090118846A (ko) 2009-11-18
SI2119448T1 (sl) 2012-02-29
HRP20110643T1 (hr) 2011-10-31
EP2119448A1 (en) 2009-11-18
JP5623027B2 (ja) 2014-11-12
AU2009201893A1 (en) 2009-12-03
IL198545A0 (en) 2011-07-31
EA200900537A1 (ru) 2009-12-30
EP2119448B1 (en) 2011-06-22
SG157312A1 (en) 2009-12-29
CA2665958A1 (en) 2009-11-14
EA017863B1 (ru) 2013-03-29
KR101509263B1 (ko) 2015-04-06
US8404453B2 (en) 2013-03-26
US9310377B2 (en) 2016-04-12
ES2368603T3 (es) 2011-11-18
BRPI0901502A2 (pt) 2010-01-26
US20090298079A1 (en) 2009-12-03
PT2119448E (pt) 2011-09-27
MX2009005049A (es) 2009-12-18
US20120108789A1 (en) 2012-05-03
US20130183690A1 (en) 2013-07-18
PL2119448T3 (pl) 2011-11-30
CA2665958C (en) 2014-01-07
JP2009291191A (ja) 2009-12-17
ATE513556T1 (de) 2011-07-15
DK2119448T3 (da) 2011-09-26

Similar Documents

Publication Publication Date Title
CY1111853T1 (el) Θεση δεσμευσης υψηλης συγγενειας στον hgfr και μεθοδοι ταυτοποιησης ανταγωνιστων αυτου
CY2017013I2 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
CY1120267T1 (el) Αντισωματα ανταγωνιστες κατευθυνομενα εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης για την θεραπευτικη αγωγη αθροιστικης κεφαλαλγιας
NL300936I2 (nl) Semaglutide
DE602006007698D1 (de) Maschine zur Zubereitung von Getränken mit Funktionsvorrichtung und Fußaufbau
ATE442876T1 (de) Nadelfreie transdermale transportvorrichtung
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
DK1771474T3 (da) Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
DK1998805T3 (da) Tumorterapi med et antistof til vaskulær endotelial vækstfaktor og et antistof til human epitelial vækstfaktor receptor type 2
DE602006019033D1 (de) Fahrendes Objekt und dessen Steuerungsverfahren
BRPI0913793A2 (pt) "método para comunicação de estruturas nodais com dispositivo móvel ou portátil e respectivo dispositivo"
DK2061814T3 (da) Antistoffer og immunokonjugater og anvendelse deraf.
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
DK2068909T3 (da) Modificerede FGF-21-polypeptider og anvendelse heraf
DE602005002853D1 (de) Vorrichtungen zum Reparieren von lebendem Gewebe
DE602005015238D1 (de) Prothese für Annuloplastie mit auxetischer Struktur
EA016245B9 (ru) Антитела против альфа2-интегрина и их применение
DE602006018166D1 (de) Polyrotaxanhaltige lösung und verwendung davon
DE602005015841D1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
DK1910270T3 (da) For PPAR-receptorer og EGF-receptorer specifikke forbindelser og deres salte samt deres anvendelse på det medicinske område
BRPI0813309A2 (pt) Capsídeo, mistura de capsídeos, proteína quimérica, métodos para produzir o capsídeo, e para produzir a mistura de capsídeos, e, complexo de hemicianina de lapa e epítopo l2 de papilomavírus humano 16.
DE502005007017D1 (de) Filznadel
DE502006006105D1 (de) Matrize mit kleinen näpfchenartigen vertiefungen
DE602005022686D1 (de) Einpressmörtelmischung zur verwendung bei einer spannbetonkonstruktion
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo